Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based pharmaceutical company BioChemics has signed a research collaboration agreement with Cynosure, a developer and manufacturer of light-based aesthetic treatment systems, to evaluate the use of BCI's Vale based compositions in conjunction with light based aesthetic treatments.
Subscribe to our email newsletter
BioChemics (BCI) has developed a novel, transdermal drug delivery system called Vale (vaso-active lipid encapsulated), that allows a wide variety of actives to be delivered into the skin.
John Masiz, president of BioChemics, said: “We are delighted to be working with Cynosure to evaluate broader applications of our Vale based technology for light based procedures.”